This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mitsui, Y. Articles by Okada, Y. Search for Related Content PubMed PubMed Citation Articles by Mitsui, Y. Articles by Okada, Y.

ADAM28 Is Overexpressed in Human Breast Carcinomas: Implications for Carcinoma Cell Proliferation through Cleavage of Insulin-like Growth Factor Binding Protein-3

Departments of ¹ Pathology and ² Surgery, School of Medicine, Keio University, Shinjuku-ku, Tokyo, Japan

Requests for reprints: Yasunori Okada, Department of Pathology, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku-ku Tokyo 160-0016, Japan. Phone: 81-3-5363-3763; Fax: 81-3-3353-3290; E-mail: okada{at}sc.itc.keio.ac.jp.

A disintegrin and metalloproteinases (ADAMs) are involved in various biological events including cell adhesion, cell fusion, membrane protein shedding, and proteolysis. In the present study, our reverse transcription-PCR analysis showed that among the 12 different ADAM species with a putative metalloproteinase motif, prototype membrane-anchored ADAM28m and secreted-type ADAM28s are selectively expressed in human breast carcinoma tissues. By real-time quantitative PCR, their expression levels were significantly higher in carcinomas than in nonneoplastic breast tissues. In situ hybridization, immunohistochemistry, and immunoblotting analyses indicated that ADAM28 is predominantly expressed in an active form by carcinoma cells within carcinoma tissues. A direct correlation was observed between mRNA expression levels and proliferative activity of the carcinoma cells. Treatment of ADAM28-expressing breast carcinoma cells (MDA-MB231) with insulin-like growth factor-I (IGF-I) increased cell proliferation, cleavage of IGF binding protein (IGFBP)-3, as well as IGF-I cell signaling; these processes were all significantly inhibited by treatment with ADAM inhibitor or anti-ADAM28 antibody. Down-regulation of ADAM28 expression in MDA-MB231 cells with small interfering RNA significantly reduced cell proliferation, IGFBP-3 cleavage, and growth of xenografts in mice. In addition, cleavage of IGFBP-3 in breast carcinoma tissues was correlated with ADAM28 expression levels and inhibited by treatment with ADAM inhibitor or anti-ADAM28 antibody. These results show that ADAM28 is overexpressed in an activated form in human breast carcinoma cells and suggest that ADAM28 is involved in cell proliferation through enhanced bioavailability of IGF-I released from the IGF-I/IGFBP-3 complex by selective IGFBP-3 cleavage in human breast carcinomas. (Cancer Res 2006; 66(20): 9913-20)

This article has been cited by other articles:

				S. Jogie-Brahim, D. Feldman, and Y. Oh Unraveling Insulin-Like Growth Factor Binding Protein-3 Actions in Human Disease Endocr. Rev., August 1, 2009; 30(5): 417 - 437. [Abstract] [Full Text] [PDF]

				Y. Adachi, R. Li, H. Yamamoto, Y. Min, W. Piao, Y. Wang, A. Imsumran, H. Li, Y. Arimura, C.-T. Lee, et al. Insulin-like growth factor-I receptor blockade reduces the invasiveness of gastrointestinal cancers via blocking production of matrilysin Carcinogenesis, August 1, 2009; 30(8): 1305 - 1313. [Abstract] [Full Text] [PDF]

				N. Hattori, S. Mochizuki, K. Kishi, T. Nakajima, H. Takaishi, J. D'Armiento, and Y. Okada MMP-13 Plays a Role in Keratinocyte Migration, Angiogenesis, and Contraction in Mouse Skin Wound Healing Am. J. Pathol., August 1, 2009; 175(2): 533 - 546. [Abstract] [Full Text] [PDF]

				T Yatabe, S Mochizuki, M Takizawa, M Chijiiwa, A Okada, T Kimura, Y Fujita, H Matsumoto, Y Toyama, and Y Okada Hyaluronan inhibits expression of ADAMTS4 (aggrecanase-1) in human osteoarthritic chondrocytes Ann Rheum Dis, June 1, 2009; 68(6): 1051 - 1058. [Abstract] [Full Text] [PDF]

				K.-E. Kim, H. Song, C. Hahm, S. Y. Yoon, S. Park, H.-r. Lee, D. Y. Hur, T. Kim, C.-h. Kim, S. I. Bang, et al. Expression of ADAM33 Is a Novel Regulatory Mechanism in IL-18-Secreted Process in Gastric Cancer J. Immunol., March 15, 2009; 182(6): 3548 - 3555. [Abstract] [Full Text] [PDF]

				C. Fottner, S. Sattarova, K. Hoffmann, G. Spottl, and M. M Weber Elevated serum levels of IGF-binding protein 2 in patients with non-seminomatous germ cell cancer: correlation with tumor markers {alpha}-fetoprotein and human chorionic gonadotropin Eur. J. Endocrinol., September 1, 2008; 159(3): 317 - 327. [Abstract] [Full Text] [PDF]

				I. Hers Insulin-like growth factor-1 potentiates platelet activation via the IRS/PI3K{alpha} pathway Blood, December 15, 2007; 110(13): 4243 - 4252. [Abstract] [Full Text] [PDF]

				M. Shimoda, G. Hashimoto, S. Mochizuki, E. Ikeda, N. Nagai, S. Ishida, and Y. Okada Binding of ADAM28 to P-selectin Glycoprotein Ligand-1 Enhances P-selectin-mediated Leukocyte Adhesion to Endothelial Cells J. Biol. Chem., August 31, 2007; 282(35): 25864 - 25874. [Abstract] [Full Text] [PDF]